DOI: https://doi.org/10.24959/uekj.19.31

The analysis of immunostimulants assortment on the Ukrainian pharmaceutical market

M. V. Rybalkin, I. V. Demydova

Abstract


Today there is a question of searching for prospective methods of candidiasis therapy aimed at immunity stimulating and restoring the qualitative and quantitative composition of women’s microflora.
Aim. To make an analysis of immunostimulants on the Ukrainian pharmaceutical market.
Materials and methods. The immunostimulants assortment was analyzed using the classification of ATS according to the State Register of Medicines of Ukraine, October 2019.
Results. The marketing analysis presents the classification, mechanism of drug effect, countries of manufacture, types of dosage forms for immunostimulants. According to the classification of ATS L03A «Immunostimulants», it was determined that it consists of several subgroups, namely: L03A A – colony-stimulating factors, 12 drugs (9.76 %); L03A B – interferon preparations, 61 drugs (49.59 %); L03A C – interleukin preparations, 0 drugs; L03A X – other immunostimulants; 50 drugs (40.65 %). According to the results obtained, countries manufacturing immunostimulants, it was found that the main countries importing immunostimulants are: USA 5,83 %, Israel 4,50 %, Slovenia and Switzerland 3,85 % each, Germany 3,21 %. Ukrainian manufacturers supply 69.03 % of immunostimulants of the total. According to the analysis of dosage forms presented on the pharmaceutical market in Ukraine, it was found that immunostimulants are represented by types of dosage forms. The main ones are injection solution 35,03 %, lyophilized injection powder 30,57 %, suppositories 10,83 %, tincture for oral use 5,73 %, oral drops 2.55 %, syrup 1.91 %.

Conclusions. The analysis of immunostimulating drugs assortment on the pharmaceutical market in Ukraine showed that dosage form of suppositories is widespread enough. And suppositories containing interferon in combination with other drugs, that is, complex effect, are not represented at all. Therefore, it is relevant to develop the composition and technology of a new domestic combined drug in the form of suppositories based on immunostimulant, antifungal drugs and probiotics for the treatment of candidiasis.


Keywords


immunostimulants; interferon; pharmaceutical market of Ukraine; dosage form; candidiasis

References


Sergeev, A. Yu. (2018). Immunitet pri kandidoze. Mezhdunarodnyj nauchno-prakticheskij zhurnal po immunologii i infektologii, 2, 18-20.

Deorukhkar, S. ., & Saini, S. (2015). Candidiasis: Past, present and future. International Journal of Infectious and Tropical Diseases, 2(1), 12–24. https://doi.org/10.14194/ijitd.2.1.2

Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018). An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis. Journal of Fungi, 4(4), 121. https://doi.org/10.3390/jof4040121

De Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. do S., Filho, A. K. D. B., do Nascimento, F. R. F., … de Andrade Monteiro, C. (2018). Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. Frontiers in Microbiology, 9. https://doi.org/10.3389/fmicb.2018.01351

Rybalkin, M. V., Filimonova, N. I., Strilets, O. P., Strelnykov, L. S. (2014). Liky Ukrainy, 2, 25–27.

Rybalkin, M. V., Strelnykov, L. S., Strilets, O. P. (2017). Zbirnik naukovih prac spivrobitnikiv NMAPO imeni P. L. Shupika, 28, 108–115.

Derzhavnij reyestr likarskih zasobiv Ukrayini. (n.d.). Available at: http://www.drlz.com.ua/


GOST Style Citations


1. Сергеев, А. Ю. Иммунитет при кандидозе / А. Ю. Сергеев // Международный научно-практ. журн. по иммунол. и инфектол. – 2018. – № 2. – С. 18–20.

 

2. Deorukhkar, S. C. Candidiasis : Past, present and future / S. C. Deorukhkar, S. Saini // Int. J. Infect. Trop. Dis. – 2015. – № 2. – P. 12–24. https://doi.org/10.14194/ijitd.2.1.2

 

3. Makanjuola, O. An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis / O. Makanjuola, F. Bongomin, S. A. Fayemiwo // J. Fungi. – 2018.– № 4. – P. 21. https://doi.org/10.3390/jof4040121

 

4. Candida Infections and Therapeutic Strategies: Mechanisms of action for Traditional and Alternative Agents / C. G. S. Oliveira, C. C. Vasconcelos, A. J. O. Lopes, M. S. C. Sousa // Front Microbiol. – 2018. – № 9. – Р. 1351. https://doi.org/10.3389/fmicb.2018.01351

 

5. Терапевтична дія інактивованих клітин грибів C. Albicans та C. Tropicalis / М. В. Рибалкін, Н. І. Філімонова, О. П. Стрілець, Л. С. Стрельников // Ліки України. – 2014. – № 2. – С. 25–27.

 

6. Рибалкін, М. В. Маркетингові дослідження ринку протигрибкових лікарських засобів / М. В. Рибалкін, Л. С. Стрельников, О. П. Стрілець // Збірник наукових праць співробітників НМАПО імені П. Л. Шупика. – 2017. – Вип. 28. – С. 108–115.

 

7. Державний реєстр лікарських засобів України. [Електронний ресурс]. – Режим доступу : http://www.drlz.com.ua/





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Manag. econ. qual. assur. pharm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)